Ava Fertility Tracker

Strengths

• **Collects only data clearly necessary for its purpose?** Yes. Collects physiological parameters — skin temperature, resting pulse, heart-rate variability ratio, perfusion, breathing rate — directly tied to its stated purpose of predicting the ovulation window via machine-learning algorithms.
• **Purposes stated for each data type? ** Yes. The policy explains these physiological signals act as markers for fluctuating hormone levels, letting the algorithm detect the menstrual-cycle phase.
• **Can users request deletion of their data?** Yes. The policy states users can delete their data at any time.
• **Is the privacy policy easy to find?** Yes. Links are placed in the footer of the AvaWomen homepage and other key sections.
• **Specifically names the data types collected?** Yes. Identifies categories such as skin temperature, pulse rate, and breathing rate, rather than only generic “personal information” labels.
• **Requires explicit opt-in consent?** Yes. Enrollment includes explicit checkboxes consenting to personal-data processing and agreeing to the privacy policy.

Weaknesses

• **Data sharing limited to named, specific partners?** No. The policy claims no data is shared with third parties. However, the website's Privacy Preference Center mentions “advertising partners” and “social media services” that may set cookies to build interest profiles, but it does not provide a specific list of names.
• **Public controversy about data handling?** Yes. Three documented issues with their data handling. (1) Data access and loss: after FemTec Health's dissolution, many users reported account lockouts, syncing failures, and loss of years of cycle and pregnancy data tied to server-side validation that was no longer maintained. (2) Corporate oversight: parent-company founder and current CEO at Ava, Dr. Kimon Angelides, was previously named in litigation in which his firm was accused of discovery abuses and failure to properly maintain electronic records. (3) Support abandonment: users report a lack of human response to inquiries about data loss and account access.

What We Couldn't Find

• **Can users export or download their data?** Mixed. A “Cycle Report” feature provides an overview of the last 12 recorded cycles and can be downloaded from the app to keep or share with a clinician. It is unclear whether users can export their full raw physiological dataset, and some users report losing years of data when the app becomes inaccessible.
• **Written in plain, understandable language?** Mixed. Uses standard legal headers in places, but also includes clear explanations of data handling, for example, that data is stored anonymously with PII kept separate.
• **Granular privacy controls?** Unclear. Users can activate or deactivate which parameters they see in app settings, but it is unclear whether this stops backend collection or only hides data from the interface.
• **Straightforward data deletion process?** Unclear. The ability to request deletion is confirmed, but sources do not specify whether it is an automated in-app action or a manual email request.
• **Can users withdraw consent after granting it?** Unclear. Sources do not state whether a user can disable data collection while retaining core functionality.
• **Can users opt out of third-party data sharing?** Unclear. The Privacy Preference Center lets users decline certain cookie categories, including targeting and social-media cookies. Without a named partner list, the practical scope of opt-out is unclear.
• **Is only de-identified or aggregated data shared?** Mixed. User data is stored anonymously, with user IDs and registration info kept separate from PII. This sits in tension with the cookie disclosure above: advertising/social cookies that build interest profiles are not obviously limited to de-identified data, so the “anonymous storage” claim and the cookie practice are not fully reconciled in the sources.
• **Does it state it uses encryption?** Partial. Data-safety information indicates data is “encrypted in transit.” At-rest encryption is not addressed in the policies, so much more information is needed to properly assess.
• **Holds relevant security certifications?** Unclear. The company states that it abides by the GDPR (the EU standard) and uses Amazon Web Services for its security measures, but it does not mention specific certifications such as SOC 2 or ISO 27001.

Strengths

• **FDA clearance or approval?** Yes. Received FDA 510(k) clearance in December 2020, being the first wearable cleared to aid in ovulation prediction. This clearance attaches to the device and its record and does not lapse because the company changed hands; it remains a fact regardless of current operating status.
• **Registered with other regulatory bodies?** Yes. Received a CE mark under EU Medical Device Regulation (EU MDR) in January 2021; historically sold in 36 countries. Like the FDA clearance, the certification itself is durable, though current distribution and post-market surveillance under the present operator are not confirmed in the sources.
• **Any studies conducted independently?** Yes, with mixed findings. An independent validity study by researchers at the University of North Carolina at Chapel Hill (published 2022) found sleep duration moderately accurate, but heart-rate estimates not equivalent to gold-standard criterion measures in free-living conditions.
• **Clear disclaimers about limitations?** Yes. Explicitly states it is not a contraceptive method and is not intended for women with irregular cycles (outside 24–35 days) or those with PCOS.

Weaknesses

• **Adequate sample sizes and rigorous design?** Mixed. Most company-sponsored studies are prospective observational or diagnostic-accuracy studies with sample sizes of roughly 57–237 participants — more rigorous than small pilots, but not large-scale blinded randomized controlled trials.
• **Is current accuracy/efficacy validated as the product degrades?** No. Ava stated a 90% accuracy rate for detecting the five-day fertile window in real time, grounded in its published studies. However, with the current leadership, many users report that the backend no longer reliably writes data to the server (so the prediction algorithm does not update), and there is no current validation that the stated accuracy still holds for the product as it now functions. The efficacy figure is historical; its present-day applicability is unverified.
• **Are medical professionals actively involved in development?** No.
• Under the original founders, the company employed recognized women's health leaders, including a Chief Medical Officer (MD, PhD) and a Chief Scientific Officer. Currently, no medical or scientific staff are identified for Ava, and no clinical oversight under the present ownership can be confirmed.
• **Do independent expert or media reviews exist?** Mixed. Reviewed by health publications (Medical News Today) and consumer platforms (Mama Natural), and featured in The New York Times and Forbes. As with the studies, much of this coverage dates to the product's active period.
• **Are current reviews positive about accuracy/reliability?** No, sentiment has reversed. Early expert reviews were often positive about the technology's potential. Currently, more recent reviews and the independent UNC study highlight reliability issues, and current user sentiment is highly negative, citing syncing failures, data loss, and lack of support following the parent company's collapse. The trajectory runs from positive (historical) to negative (current).
• **Distinguishes clinical vs. wellness features?** Mixed. It is a cleared medical device for fertility, but the app also integrates wellness tracking (sleep, physiological stress) without always clearly labeling the regulatory distinction for those secondary features.
• **Is current marketing truthful and not overpromising?** No. Under the original leadership, claims were science-backed and tied to the published record. Under the current leadership, the remaining marketing advertises a “12-month guarantee” that users report is no longer honored. Multiple independent user reports describe a product that continues to operate commercially, even as its technical backend and customer support have degraded to what some observers have termed “zombie infrastructure”: the storefront and app remain active and continue to charge customers, while engineering, server support, and human customer service have largely lapsed.

What We Couldn't Find

• **Peer-reviewed studies supporting its claims?** Unclear. The company cites 30+ peer-reviewed publications and presentations, with studies in journals including the Journal of Medical Internet Research, Scientific Reports, and Bioscience Reports. However, essentially all of this body of work predates the 2023 transition; there is no evidence of new validation since.
• **Are there named partnerships with hospitals or academic institutions?** Unclear. Ava cites research collaborations with the University Hospital of Zurich and Northwestern University. However, these collaborations are tied to the pre-2023 company and its clinical programs; the sources show no evidence they remain active under the current operator.
• **Are there partnerships for research purposes?** No. Post-2023 leadership transition, no ongoing research activity is evident.

Strengths

• **Is current marketing respectful and educational?** Mixed. The remaining marketing tone is empowering and educational, focused on helping women “take charge” of their cycles. The concern is not tone but accuracy (see weaknesses).

Weaknesses

• **Is there a specific, actionable women's health mission?** Mixed. Both Ava's original mission and the current parent's stated mission (“support and solutions for the most underserved, stigmatized, and neglected women's health concerns”) are specific. But as an actionable mission for Ava, it is not currently being realized: the research engine that once embodied it has lapsed, and the product's backend is reported as failing.
• **Is the mission reflected in current product decisions and actions?** No. Historically, the mission produced 30+ peer-reviewed studies and clinical trials. Under Awesome Health, the Ava product itself is reported to experience syncing failures, data loss, and a lack of support, suggesting that ownership has not translated into operational maintenance. Observers have described the brand as “zombie infrastructure.”
• **Do advisors appear to have active, ongoing roles?** No. There is no evidence of active clinical oversight under current ownership; the sources indicate this involvement has lapsed.
• **Is the company currently publishing research or presenting at conferences?** Not under current leadership. A robust academic record, including 30+ peer-reviewed publications (Scientific Reports, JMIR) and presentations at conferences such as ASRM. However, no ongoing research output or conference activity for Ava has been found since the 2023 transition.
• **Does the company currently engage in public advocacy or education?** No, only static content remains. The AvaWorld blog still hosts educational content (hormonal shifts, COVID-19 vaccination in pregnancy, basal body temperature), so that material remains available. The current parent also centers on women's health education. But there is no evidence of ongoing newly produced advocacy or education specific to Ava; what remains for the brand appears to be legacy content.
• **Does current marketing align with stated mission and values?** Mixed. The Ava and Awesome Health messaging share a consistent women's health mission, so they align. What pulls this to Mixed is the gap between message and operation: a mission centered on supporting women's health, paired with a product reported to be failing and unsupported under the same ownership.
• **Is current marketing free of exploitative or misleading tactics?** No. Users report the “12-month money-back guarantee” is functionally impossible to claim, alleging they could not reach support after meeting refund requirements, and that the automated site continues to collect payment for a product reported to suffer syncing failures.

What We Couldn't Find

• **Do current leaders have direct women's health or clinical expertise?** Unclear. The original founding team came from business and technology rather than medicine. Currently, the brand sits under Awesome Health, whose founder, Kimon Angelides, has an extensive healthcare-founder background (per his self-authored profile, founder of seven healthcare companies, including Livongo). However, his CEO role at the successor company is listed as ending in 2024, and no current clinical leadership for Ava specifically is identified, so present-day clinical oversight cannot be confirmed.
• **Do current leaders have relevant healthcare/health-tech experience?** Mixed. It is unclear who is actively running the Ava brand today, given CEO Kimon Angelides’s stated 2024 Awesome Health departure and the company's minimal public footprint (a LinkedIn page citing 51–200 employees but only a handful of associated members).
• **Is current leadership information publicly available and verifiable?** Mixed. Historically, detailed, verifiable bios existed for the founders. But currently, the parent company (Awesome Health) and an associated founder can be identified, but the information is self-reported on LinkedIn, is not corroborated by registry-based sources, and does not name who operates Ava day-to-day.
• **Is there a current named advisory board or clinical consultants?** Unclear. None identified currently. Neither the Ava brand nor the Awesome Health parent identifies any clinical consultants or advisory board members in active roles in the available sources.
• **Do current advisors have relevant women's health credentials?** Unclear. As no current advisors are identified, present-day credentials cannot be assessed.

Strengths

• **Available in multiple languages?** Yes. The website offers English, Deutsch, Español, Français, Italiano, Polski, and čeština; the App Store listing indicates additional languages including Arabic, Russian, Chinese, Korean, Portuguese, and Vietnamese.

Weaknesses

• **Meets basic accessibility standards?** No. A June 2026 accessibility scan of the Ava website (avawomen.com) found it non-compliant, with 50 detected issues (31 critical, 18 serious): buttons lacking visible text labels, interactive elements not identified as buttons, and missing screen-reader cues for the current page. (The scan covered the avawomen.com storefront — which remains live and transacting — not the iOS/Android app; automated scans catch much but not all issues.)
• **Usable across varying tech literacy?** Mixed. Some reviewers describe the device and app as easy to use, but the accessibility audit identified 13 interactive-content and 7 text-content issues that could hinder usability, and some users reported the app felt “clunky” (e.g., not remembering cycle start dates when switching to pregnancy mode).
• **Diverse racial/ethnic representation in marketing imagery?** Mixed. Marketed to ages 18–45; the bracelet is described as adjustable to a wide range of wrist sizes. Marketing features testimonials from women with diverse names (e.g., “Anu,” “Kate,” “Zoe,” “Rachel”). Academic critiques of the broader femtech sector note that fertility apps often reinforce a focus on “white middle-class privileged femininity.”
• **Language inclusive of LGBTQ+ and gender-diverse users?** Mixed. The core mission is “advancing women's health,” and marketing consistently refers to the “female body” and “women.” Academic analysis notes this gendered focus and related design choices can create feelings of exclusion for gender and sexual minorities.
• **Free tier with meaningful functionality?** No. The app is a free download, but must be used with the Ava bracelet. There is no standalone free tier that provides core fertility predictions without purchasing hardware.
• **Paid tier reasonably priced for the target audience?** Mixed. At roughly $239–$359, the device is described as pricey and a significant investment, though it is positioned as preventive care that may reduce the need for costlier fertility interventions.
• **Evidence the product was tested with diverse user groups?** Mixed. Ava has 30+ peer-reviewed studies, but the independent UNC validity study had a participant pool that was 70% non-Hispanic White. Academic sources note that many fertility apps are developed and tested within demographics that reinforce privileged femininity.
• **Accommodates different bodies, cycles, or health conditions?** Mixed. Physically inclusive (fits wrists 12.5–20.5 cm), but restrictive on cycle health: not intended for irregular cycles outside the 24–35-day range, not tested for PCOS, and unsuitable for those with implanted devices like pacemakers.

What We Couldn't Find

• **Offers financial assistance or insurance coverage?** Unclear. The bracelet is FSA- and HSA-eligible and has been reimbursed by many companies as an employer health benefit, with a financing option available. One distinction worth noting: FSA/HSA eligibility is a durable product-category fact (a fertility device qualifies as a medical expense). The employer-benefit reimbursement and financing arrangements, however, depend on active business relationships and a functioning company behind them, the same thing now in doubt, so those may be legacy claims from the FemTec and Awesome Health era that are no longer actively administered.
• **Partners with community health organizations?** Unclear. May have corporate and benefit partnerships (e.g., Aristo Pharma, Carrot, WINFertility) and clinical-research collaborations (Northwestern, University Hospital of Zurich), but no specific mention of partnerships with community organizations serving underserved or marginalized populations. Unclear what is active.
• **Outreach to underserved or marginalized communities?** Unclear. Ava website does not highlight specific programs or free-access initiatives targeting health equity.
• **Engages with feedback from diverse communities?** Unclear. Engages users via an online community included with product bundles and surveyed 1,756 users about their conception journeys, but it is unclear whether these efforts specifically target or respond to diverse communities' needs.